This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

AVROBIO Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

AVROBIOs Gewinne werden voraussichtlich um 0.8% pro Jahr sinken. Der Gewinn pro Aktie wird voraussichtlich sinken um 23.8% pro Jahr.

Wichtige Informationen

-18.4%

Wachstumsrate der Gewinne

-18.0%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.5%
Wachstumsrate der Einnahmen	n/a
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	04 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Avrobio rises as gene therapy for Gaucher disease gets ILAP designation in UK

Oct 18

Avrobio stock rises as kidney disease gene therapy gets FDA rare pediatric disease status

Sep 20

Here's Why We're Not Too Worried About AVROBIO's (NASDAQ:AVRO) Cash Burn Situation

Mar 08

AVROBIO: Undercovered Gene Therapy Developer With Excellent Promise

Dec 25

We Think AVROBIO (NASDAQ:AVRO) Can Afford To Drive Business Growth

Nov 23

AVROBIO readies $75M equity offering

Nov 19

AVROBIO EPS misses by $0.19

Nov 05

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:AVRO - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	N/A	-2	N/A	N/A	1
12/31/2025	N/A	-7	N/A	N/A	1
12/31/2024	N/A	-21	N/A	N/A	1
3/31/2024	N/A	30	-50	-50	N/A
12/31/2023	N/A	12	-63	-63	N/A
9/30/2023	N/A	-4	-79	-79	N/A
6/30/2023	N/A	-5	-75	-75	N/A
3/31/2023	N/A	-101	-90	-89	N/A
12/31/2022	N/A	-106	-97	-97	N/A
9/30/2022	N/A	-109	-101	-99	N/A
6/30/2022	N/A	-119	-109	-108	N/A
3/31/2022	N/A	-122	-101	-99	N/A
12/31/2021	N/A	-119	-100	-98	N/A
9/30/2021	N/A	-119	-104	-103	N/A
6/30/2021	N/A	-123	-104	-103	N/A
3/31/2021	N/A	-121	-104	-104	N/A
12/31/2020	N/A	-120	-100	-99	N/A
9/30/2020	N/A	-114	-89	-87	N/A
6/30/2020	N/A	-95	-77	-75	N/A
3/31/2020	N/A	-82	-74	-72	N/A
12/31/2019	N/A	-73	-69	-68	N/A
9/30/2019	N/A	-66	-62	-61	N/A
6/30/2019	N/A	-61	-61	-59	N/A
3/31/2019	N/A	-55	-51	-49	N/A
12/31/2018	N/A	-49	-39	-38	N/A
9/30/2018	N/A	-40	-36	-35	N/A
6/30/2018	N/A	-35	-27	-26	N/A
3/31/2018	N/A	-27	-21	-20	N/A
12/31/2017	N/A	-19	N/A	-16	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: AVROFür die nächsten 3 Jahre wird ein Rückgang der Gewinne prognostiziert (-0.8% pro Jahr).

Ertrag vs. Markt: AVROFür die nächsten 3 Jahre wird ein Rückgang der Gewinne prognostiziert (-0.8% pro Jahr).

Hohe Wachstumserträge: AVROFür die nächsten 3 Jahre wird mit einem Rückgang der Erträge gerechnet.

Einnahmen vs. Markt: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von AVRO schneller wachsen werden als der Markt von US.

Hohe Wachstumseinnahmen: AVRO wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von AVRO in 3 Jahren voraussichtlich hoch sein wird

This company is no longer active

AVROBIO Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

No longer forecast to breakeven

Price target decreased by 16% to US$3.00

Price target decreased by 8.5% to US$3.58

Price target decreased to US$4.14

Price target decreased to US$6.29

Price target decreased to US$22.88

Recent updates

Tectonic Therapeutic, Inc. completed the acquisition of AVROBIO, Inc. (NasdaqGS:AVRO) from a group of shareholders in a reverse merger transaction.

Investor sentiment improves as stock rises 1,043%

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

New minor risk - Shareholder dilution

AVROBIO, Inc. (NasdaqGS:AVRO) entered into an agreement to acquire Tectonic Therapeutic, Inc.

AVROBIO, Inc. (NasdaqGS:AVRO) entered into an agreement to acquire Tectonic Therapeutic, Inc.

No longer forecast to breakeven

Price target decreased by 16% to US$3.00

New major risk - Revenue and earnings growth

Chief Business Officer notifies of intention to sell stock

Novartis Pharma AG and Novartis Pharmaceuticals Corporation entered into an Asset Purchase Agreement to acquire Cystinosis Gene Therapy Program from AVROBIO, Inc. (NasdaqGS:AVRO) for $87.5 million.

Price target decreased by 8.5% to US$3.58

Novartis Pharma AG and Novartis Pharmaceuticals Corporation entered into an Asset Purchase Agreement to acquire Cystinosis Gene Therapy Program from AVROBIO, Inc. (NasdaqGS:AVRO) for $87.5 million.

Co- Founder exercised options to buy US$104k worth of stock.

AVROBIO, Inc. Announces New Positive Clinical Data and Outlines Clinical Development Plan Following Regulatory Discussions for Its Gaucher Disease Gene Therapy

Price target decreased to US$4.14

Insufficient new directors

Avrobio Receives Rare Pediatric Disease Designation from the U.S. FDA for First-In-Class Gene Therapy for Gaucher Disease

AVROBIO, Inc. Announces Completion of Patient Dosing in First Gene Therapy Clinical Trial for Cystinosis

AVROBIO, Inc. announces U.K. Medicines and Healthcare products Regulatory Agency grant an Innovation Passport under the Innovative Licensing and Access Pathway

Avrobio rises as gene therapy for Gaucher disease gets ILAP designation in UK

AVROBIO, Inc. Reports Favorable Data on Use of Combined State-Of-The-Art in Vitro Cell-Based Assays to Identify Potential Genotoxicity Risk of Integrating Vectors During Preclinical Development

AVROBIO Receives Written Notice from The Nasdaq Stock Market Regarding Minimum Bid Price Requirement

AVROBIO, Inc. Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for First Gene Therapy in Development for Cystinosis

Avrobio stock rises as kidney disease gene therapy gets FDA rare pediatric disease status

AVROBIO Inc. Announces Neuronopathic Mucopolysaccharidosis Type II or Hunter Syndrome Clinical Trial Application Accepted by U.K. Regulatory Agency to Initiate Pediatric Phase 1/2 Gene Therapy Trial

AVROBIO granted FDA’s orphan drug designation for metabolic disorder therapy

AVROBIO, Inc.(NasdaqGS:AVRO) dropped from Russell 2500 Index

AVROBIO, Inc. Announces Preclinical Data Demonstrating the Efficacy and Safety of AVR-RD-03 Gene Therapy in A Mouse Model of Infantile Onset Pompe Disease

Avrobio Reports Positive Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis, Including New Interim Data on Neurocognitive Measures

Price target decreased to US$6.29

Insufficient new directors

AVROBIO, Inc. Reports Interim Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis

Insufficient new directors

Insufficient new directors

AVROBIO, Inc. Announces the Appointment of Sean O’Bryan as Chief Regulatory Officer

AVROBIO, Inc. Announces New Data from Phase 2 Fab-Gt Clinical Trial Show Variable Engraftment

AVROBIO, Inc Presents Clinician Experience with FAB-GT Clinical Trial and Updated Safety Data for Investigational Gene Therapies in Fabry Disease and Gaucher Disease Type 1

Price target decreased to US$22.88

Price target increased to US$25.14

Here's Why We're Watching AVROBIO's (NASDAQ:AVRO) Cash Burn Situation

We're Keeping An Eye On AVROBIO's (NASDAQ:AVRO) Cash Burn Rate

AVROBIO, Inc.(NasdaqGS:AVRO) dropped from Russell 2500 Growth Index

AVROBIO: Fabrazyme's Full Approval Changes Things

AVROBIO, Inc. Provides Regulatory Update on Investigational AVR-RD-01 for Fabry Disease

AVROBIO, Inc. Announces Two Oral Presentations and Two Posters Featuring Data from Its Pipeline of Lysosomal Disorder Gene Therapy

Here's Why We're Not Too Worried About AVROBIO's (NASDAQ:AVRO) Cash Burn Situation

Price target lowered to US$34.50

AVROBIO, Inc. Receives Orphan Drug Designation from the European Commission for AVR-RD-04, an Investigational Gene Therapy for Cystinosis

AVROBIO, Inc. Announces 100% Kidney Substrate Reduction at 12 Months Post-Gene Therapy in First Patient Dosed with plato Gene Therapy Platform in Fabry Disease Phase 2 Trial

New 90-day high: US$17.11

Avrobio Appoints Diana M. Escolar as Chief Medical Officer

AVROBIO, Inc. Appoints Diana M. Escolar as Chief Medical Officer

AVROBIO: Undercovered Gene Therapy Developer With Excellent Promise

We Think AVROBIO (NASDAQ:AVRO) Can Afford To Drive Business Growth

AVROBIO readies $75M equity offering

AVROBIO, Inc. Avrobio Announces New Positive Clinical Data and Preclinical Data, as Well as Expanded Leading Lysosomal Disorder Gene Therapy Pipeline

AVROBIO EPS misses by $0.19

Price target raised to US$38.50

Avrobio, Inc. Enters into Agreement with University of Manchester, England

Avrobio, Inc. Receives Orphan Drug Designation from the European Medicines Agency for Avr-Rd-02, an Investigational Gene Therapy for Gaucher Disease

New 90-day low: US$15.00

New 90-day low - US$15.85

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite